

**CLAIMS**

1. Use of an extract of animal, plant or  
5 microorganism-produced origin that comprises  
docosahexaenoic acid as active substance for the  
manufacture of a medicament for the treatment of  
lipodystrophy in a mammal.

2. Use according to Claim 1, characterised in that  
10 the amount of docosahexaenoic acid in said extract is  
higher than or equal to 100 mg/day.

3. Use according to Claim 2, characterised in that  
said amount of docosahexaenoic acid in said extract is 4  
grams/day.

15 4. Use according to any of claims 1 to 3, in which  
the medicament promotes adipocytary differentiation.

5. Use according to any of claims 1 to 3, in which  
the medicament has hypolipemiant activity.

6. Use according to any of claims 1 to 3, in which  
20 the medicament reduces the alpha tumour necrosis factor.

7. Use according to any of claims 1 to 3, in which  
the medicament has antihypertensive activity.

8. Use according to claim 1, in which the  
medicament is capable of inhibiting the toxic effects  
25 caused by the administration of an antiretroviral drug.

9. Use according to Claim 1, in which said  
docosahexaenoic acid is present in said extract in a  
concentration which ranges between 5% and 100% (w/w).

10. Use according to Claim 9, in which said  
30 docosahexaenoic acid is present in said extract in a  
concentration which ranges between 50% and 100% (w/w).

11. Use according to any of the preceding claims,  
in which the medicament is administered orally.

12. Use according to any of the preceding claims,  
35 in which the drug is administered parenterally.

11

13. Use according to Claim 1, in which said mammal is a human.

14. Use according to Claim 13, in which said human is infected with the HIV virus.

5